<html xmlns="http://www.w3.org/1999/xhtml"> <head> <style type="text/css">
      	     		 
      	    a                          {background : #ffffff; }
      	    article                    {border-style : dotted; border-width : 2px; }
		 	
		 	div                        {background : #ffffcc;}
		 	div.abstract-title         {font-weight : bold ; font-size : 16pt;}
		 	div.ack                    {border-style : solid ; border-color : red; margin : 2em; }
		 	div.article-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.boxed-text             {margin : 5em; border-style : solid;}
		 	div.contrib-group          {margin : 1em; }
		 	div.fig                    {border-style : solid; border-width : 2px; margin : 2em; }
		 	div.funding                {font-weight : bold ; font-size : 16pt;}
		 	div.given-names            {font-style : italic;}
		 	div.intro                  {border-style : inset; margin : 5px;}
		 	div.introduction           {border-style : inset; margin : 5px;}
		 	div.journal-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.journal-title-group    {background : #ffeeee;}
		 	div.article-title          {font-weight : bold ; font-size : 18pt;}
		 	div.kwd                    {font-style : italic}
		 	div.meta-name              {font-weight : bold ; font-size : 16pt;}
		 	div.name                   {font-weight : bold;}
		 	div.alt-title              {font-style : italic; font-size : 12px;}
		 	
		 	div.sec                    {border : 2px; margin 5px; padding 2px;}
		 	div.title                  {font-family : courier; font-weight : bold;
		 	                            font-size : 16pt; margin : 5px;}
		 	
		 	div.materials_methods      {border-style : double; margin : 5px; }
		 	div.methods                {border-style : double; margin : 5px; }
		 	
		 	div.results                {border-style : solid; margin : 5px;}
		 	div.background             {border-style : dotted; margin : 5px;}
		 	
		 	div.discussion             {border-style : groove; margin : 5px;}
		 	div.conclusion             {border-style : ridge; margin : 5px;}
		 	div.conclusions             {border-style : ridge; margin : 5px;}
		 	div.supplementary-material {border-style : inset; margin : 5px;}
		 	div.abbreviations          {border-style : double; border-color : red; margin : 5px;}
		 	div.competinginterests     {border-style : double; border-color : blue; margin : 5px;}
		 	div.acknowledgements       {border-style : double; border-color : green; margin : 5px;}
		 	div.authors_contributions   {border-style : double; border-color : purple; margin : 5px;}
		 	
		 	div.publisher              {border-style : outset; margin : 5px;}
		 	div.fn-type-conflict       {background : #f88; }
		 	div.fn-type-con            {background : #ddf; }
		 	div.fn-type-other          {background : #ddd; }
		 	
		 	div.unknown                {background : #ffd;
									 	  border-style : solid;
									 	  border-width : 1px;
									 	  padding : 2 px;}
		 	  
      	    table                      {background : #ffffdd;}
		 	tr                         {background : #ddddff; padding : 1px;}
		 	
		 	span                       {background : #ffcccc;}
		 	
		 	span.citation-author       {font-family : helvetica; background : #ffeeee;}
		 	span.collab                {background : #ddffff; }
		 	span.comment               {font-family : courier; font-size : 6px; background : #ffaaff;}
		 	span.contrib               {background : #ffffff;}
		 	span.corresp               {background : #ddffdd; }
		 	span.doi                   {background : #ffffff;}
		 	span.email                 {font-family : courier; }
		 	span.etal                  {font-style : italic;}
		 	span.fpage                 {font-family : courier;}
		 	span.given-names           {background : #ffffff;}
		 	span.iso-abbrev            {background : #ffffff;}
		 	span.issn-epub             {background : #ffffff;}
		 	span.issn-ppub             {background : #ffffff;}
		 	span.journal-title         {background : #ffffff;}
		 	span.lpage                 {font-family : courier;}
		 	span.mixed-article-title   {font-style : italic ;}
		 	span.nlm-ta                {background : #ffffff;}
		 	span.pmc                   {background : #ffffff;}
		 	span.pmcid                 {background : #ffffff;}
		 	span.pmid                  {background : #ffffff;}
		 	span.publisher             {background : #ffffff;}
		 	span.publisher-id          {background : #ffffff;}
		 	span.publisher-name        {background : #ffffff;}
		 	span.source                {background : #ffffff;}
		 	span.subject               {background : #ffffff;}
		 	span.surname               {background : #ffffff;}
		 	span.volume                {font-family : courier; font-weight : bold;}
		 	span.year                  {font-family : courier ; font-style : italic;}
			</style> </head> <body> <div class="front" title="front"> <div class="journal-meta" tagx="journal-meta" title="journal-meta"><span class="nlm-ta" title="nlm-ta">J Transl Med</span><span class="iso-abbrev" title="iso-abbrev">J Transl Med</span><div class="journal-title-group" tagx="journal-title-group" title="journal-title-group"><span class="journal-title" tagx="journal-title" title="journal-title">Journal of Translational Medicine</span></div><span class="issn-epub" tagx="issn" title="issn-epub">1479-5876</span><div class="publisher" tagx="publisher" title="publisher"><span class="publisher-name" tagx="publisher-name" title="publisher-name">BioMed Central</span><span class="publisher-loc" tagx="publisher-loc" title="publisher-loc">London</span></div> </div> <div class="article-meta" tagx="article-meta" title="article-meta"><span class="pmcid" title="pmcid"> pmcid: <a href="http://www.ncbi.nlm.nih.gov/pubmed/7558548">7558548</a></span><span class="publisher-id" title="publisher-id">2476</span><span class="doi" title="doi"> doi: <a href="https://dx.doi.org/10.1186/s12967-020-02476-9">10.1186/s12967-020-02476-9</a></span><div class="article-categories" title="article-categories">
: <span class="subject" title="subject">Commentary</span></div> <div class="title-group" tagx="title-group" title="title-group"> <div class="article-title" title="article-title">
A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals</div> </div> <div class="contrib-group" title="contrib-group"><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chitalia</span><span class="given-names" tagx="given-names" title="given-names">Vipul C.</span></span><a href="#Aff1">1</a><a href="#Aff2">2</a></span><span class="contrib" title="contrib"><span class="contrib-id" tagx="contrib-id" title="contrib-id">http://orcid.org/0000-0001-9617-9460</span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Munawar</span><span class="given-names" tagx="given-names" title="given-names">Ali H.</span></span><span class="address" title="address"><span class="email" tagx="email" title="email">amunawar@bisect-tx.com</span></span><a href="#Aff3">3</a></span><span class="citation_author_institution" id="Aff1">[1], <div class="institution-wrap" title="institution-wrap"><span class="institution-id" title="institution-id">grid.239424.a</span><span class="institution-id" title="institution-id">0000 0001 2183 6745</span><span class="institution" title="institution">Boston University Medical Center, </span></div></span><span class="citation_author_institution" id="Aff2">[2], <div class="institution-wrap" title="institution-wrap"><span class="institution-id" title="institution-id">grid.116068.8</span><span class="institution-id" title="institution-id">0000 0001 2341 2786</span><span class="institution" title="institution">Institute for Medical Engineering &amp;amp; Science, Massachusetts Institute of Technology, </span></div></span><span class="citation_author_institution" id="Aff3">[3], </span></div><span class="pub-date-epub" title="pub-date-epub">epub: <span>2020-10-10</span></span><span class="pub-date-pmc-release" title="pub-date-pmc-release">pmc-release: <span>2020-10-10</span></span><span class="pub-date-collection" title="pub-date-collection">collection: <span>2020</span></span><span class="volume" tagx="volume" title="volume">18</span><span class="elocation-id" tagx="elocation-id" title="elocation-id">390</span><span class="history" title="history"><span class="received" title="received">received: 2020-4-18</span><span class="accepted" title="accepted">accepted: 2020-8-2</span></span><div class="permissions"><span class="copyright" title="copyright">(C) , </span><span class="license" title="license"><span class="license-p" title="license-p"><b>Open Access</b>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third-party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</a>. The Creative Commons Public Domain Dedication waiver (<a href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</a>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</span></span></div> <div class="abstract" title="abstract"> <div class="abstract-title" title="abstract-title">
Abstract</div> <p id="Par1">While the COVID-19 pandemic has spurred intense research and collaborative discovery worldwide, the development of a safe, effective, and targeted antiviralÂ from the ground up is time intensive.Â Therefore, most antiviral discovery efforts are focused on theÂ re-purposing of clinical stage or approved drugs. While emerging data on drugs undergoing COVID-19 repurpose are intriguing,Â there is an undeniable need to develop broad-spectrum antivirals to prevent future viral pandemics of unknown origin. The ideal drug to curtail rapid viral spread would beÂ a broad-acting agent with activity against a wide range of viruses. Such a drug would work by modulating host-proteins that are often shared by multiple virus families thereby enabling preemptive drug development andÂ thereforeÂ rapid deployment at the onset of an outbreak. Targeting host-pathways and cellularÂ proteins that are hijacked byÂ viruses can potentiallyÂ offer broad-spectrum targets for the development ofÂ future antiviral drugs. Such host-directed antivirals are also likely to offer a higher barrier to theÂ developmentÂ and selection ofÂ drugÂ resistant mutations. Given that mostÂ approved antivirals do not target host-proteins, we reinforce the need for the development of such antivirals that can be used in pre- and post-exposure populations.</p> </div> <div class="kwd-group"> <div class="title" tagx="title" title="title">
Keywords</div> <div class="kwd" title="kwd">
COVID-19</div> <div class="kwd" title="kwd">
Broad-spectrum antivirals</div> <div class="kwd" title="kwd">
Mechanism of action (MOA)</div> <div class="kwd" title="kwd">
Pandemics</div> <div class="kwd" title="kwd">
Drug discovery and development</div> <div class="kwd" title="kwd">
SARS-CoV-2</div> <div class="kwd" title="kwd">
Host-directed antivirals</div> <div class="kwd" title="kwd">
Antiviral drug design</div> <div class="kwd" title="kwd">
Coronavirus (CoV)</div> <div class="kwd" title="kwd">
Drug design strategies</div> <div class="kwd" title="kwd">
Prophylactic antiviral therapy</div> </div> <div class="custom-meta-group" title="custom-meta-group"> <meta name="issue-copyright-statement" value="Â© The Author(s) 2020" /> </div> </div> </div> <div class="body" title="body"> <div class="background" title="sec"> <div class="title" tagx="title" title="title">
Background</div> <p id="Par2">The exponential global spread of SARS-CoV-2, the virus behind theÂ COVID-19 pandemic, has stunned the world with a staggering socioeconomicÂ and public health impact [<a href="#CR1">1</a>]. To date, this novel coronavirus has infected over 33 million people in 213 countries and resulted in over 1 million deaths worldwide [<a href="#CR2">2</a>]. Despite SARS-CoV-2 being the seventh knownÂ coronavirus to infect humans, the therapeutic landscape has remained barren, creating an urgent demand for the development of effective therapeutics for COVID-19 patients. While effective COVID-19 management requires both antiviral and anti-inflammatory treatment strategies, the need forÂ a potent and safe antiviral for therapeutic andÂ prophylactic use is undisputed. However, theÂ expectations of developing safe and selectiveÂ antiviral agents in a short time frame are impractical given that drug development from target discovery to approval takes 12Â years on average [<a href="#CR3">3</a>]. Therefore, initial efforts have been focused on theÂ repurposing of clinical stage or approved drugs. Even with therapeuticÂ repurposing as a rapid strategy to redirect approved or clinical-stageÂ drugsÂ that were originally discovered for other diseases,Â the global community has witnessed the intricacies, nuances and challenges of drug development.</p> <p id="Par3">Of several approved drugs, in two separate in vitro studies, chloroquine (CQ) and hydroxychloroquine (HCQ) showed potent antiviralÂ activity against SARS-CoV-2 [<a href="#CR4">4</a>]. Furthermore, a non-randomized, open label study in patients infected with the SARS-CoV-2 virus in Wuhan and other parts of China showed preliminary evidence of benefit against pneumonia and the clinicalÂ course of COVID-19 [<a href="#CR5">5</a>]. This initial excitement was tempered by two large, retrospective observational trialsÂ involving HCQ which were unable to demonstrate efficacy in COVID-19 patients [<a href="#CR6">6</a>, <a href="#CR7">7</a>]. Moreover, the use of HCQ was associated with a significantly higher risk for in-hospital death, cardiac arrest, and QT interval prolongation, and other electrocardiogramÂ abnormalities [<a href="#CR8">8</a>â€"<a href="#CR10">10</a>]. As a resultÂ of these safety concerns, the use of HCQ for anti-COVID-19 management has diminished.</p> <p id="Par4">The approval of remdesivir, a nucleoside analog originally developed for the treatment Ebola virus infections, has added hopeÂ to the early management of COVID-19 infections. Remdesivir wasÂ found to have in vitro activity against SARS-CoV-2, further mechanism of action studies showed that it targets the viralÂ nsp12 polymerase and acts as a chain terminator in viral replication. Recent clinical studies involving remdesivirÂ have shown promising results as Â its use is associated with a shorter time to recovery in comparison to placebo (11Â days vs. 15Â days) [<a href="#CR11">11</a>]. While remdesivir has received FDA approval for COVID-19 treatment, challenges with manufacturing and IV-administration have limited its widespread use. A key concept that is noteworthy from the above experience is the need for broad-spectrum antivirals with diverse mechanisms of actionÂ that are readily deployable for the prevention of future pandemics of known or unknown viruses.</p> </div> <div class="direct-actingantiviralagents(daas)vs.host-directedantiviralagents(hdas)" title="sec"> <div class="title" tagx="title" title="title">
Direct-acting antiviral agents (DAAs) vs. host-directed antiviral agents (HDAs)</div> <p id="Par5">Most approved antiviral drugs target viral proteins, oftenÂ acting selectively against one virus. Historically, drug development efforts have disproportionately focused on targeting viral proteins leading to the development of direct-acting antivirals (DAAs). However, viruses exploit numerous host proteins to carry out essential steps in their life cycles, and these proteins can be targeted for the development of host-directed antiviral agents (HDAs). Since viruses from one family often employ the same host proteins, targeting these proteins can produce agents with broad-spectrum antiviral activity and offerÂ a higher barrier to the development of drugÂ resistant virus strains. A key feature of HDAs is that their development can occur prior to the discovery of a new viral pathogen. TheÂ need for HDAs is underscored by the fact that there are over aÂ dozen zoonotic viruses that have caused deadly human disease in recent yearsÂ and will remain potential sources for future outbreaks. The last decade alone has witnessed two epidemics prior to COVID-19 in the form of the 2012 MERS epidemic (caused by another coronavirus) and the 2016 Zika epidemic (caused by an arthopod-borne flavivirus).Â A pre-existing repertoire of first-line, broad-acting HDAs that can be readily deployed may be beneficial inÂ slowing theÂ initial viral spreadÂ or inÂ suppressing outbreaks. Later, HDAs can be complemented with DAAs and vaccines since their development hinges on the knowledge of specific viral proteins. While broad and deep investigation of viral-host pathways and targets is needed, the following examples illustrate a few of many cellular pathways that are utilized by different viruses, including coronaviruses, to replicate and cause infections.</p> <div class="hostproteaseinhibitiontorestrictviralentry" title="sec"> <div class="title" tagx="title" title="title">
Host protease inhibition to restrict viral entry</div> <p id="Par6">Respiratory viruses such as influenza, parainfluenza and coronaviruses rely on host proteases for the activation of their entryÂ factors that facilitate membrane fusion and entry into airway epithelial cells. The transmembrane protease serine 2 (TMPRSS2) is a ubiquitously expressed serine proteaseÂ that is crucialÂ to Â the cleavage and activation of both, hemagglutininÂ (HA) of human influenza viruses and the spike (S) protein of SARS-like coronaviruses [<a href="#CR12">12</a>]. TMPRSS2 is dispensable for host development and homeostasis and thus may constitute an attractiveÂ therapeutic target [<a href="#CR13">13</a>]. Camostat, a clinical-stage serine protease inhibitor, is able to block viral entry of SARS-CoV-2 and influenza viruses [<a href="#CR12">12</a>]. Serine proteases involved withÂ the pathogenesis of respiratory viruses are classified as trypsin-like proteases) whichÂ possess structurally conserved active site. This feature of trypsin-like proteases may be exploited for the design of inhibitorsÂ with broad-spectrum activity [<a href="#CR14">14</a>]. However, such targets are not without limitations as viruses often access molecular andÂ biologicalÂ redundancies in their host. Although camostat inhibited SARS-CoV-2 entry and replication, it did not completely abolish viral replication, likely reflecting residual S protein activation through alternative means. This is not surprising as the SARS-CoV-2 can also use the endosomal cysteine proteases cathepsin B/L to activate and prime itsÂ S protein in TMPRSS2 null cells. However, it must be noted that S protein processing by TMPRSS2, but not cathepsin B/L, is essential for viral entry [<a href="#CR15">15</a>, <a href="#CR16">16</a>].</p> <p id="Par7">Moreover, the SARS-CoV-2 possesses a multibasic cleavage site which isÂ processed by furin, another cellular protease. Furin inducedÂ pre-cleavage at the S1/S2 site likely promotes subsequent TMPRSS2-dependent entry into target cells. The presence of a furin-mediated cleavage site in viral proteins is often associated with highly pathogenic viral strains of influenzaÂ viruses [<a href="#CR17">17</a>]. Also, furin-mediated cleavage has been described for the processing of several viral glycoproteins across diverse viral families, including Borna-, Bunya-, Corona-, Filo-, Flavi-, Herpes-, Orthomyxo-, Paramyyxo-, Pneumo-, Retro- and Toga viruses [<a href="#CR17">17</a>]. In general, processing by furinÂ can occur during viral production before egress from the producer cell or in the extracellular space during entry into target cells. Collectively, the presence of multiple exo- and endo- proteases offer drug design opportunities that may be efficiently accessed through drug combination strategies.</p> </div> <div class="depletionofintracellularnucleotidepoolsandenhancementofviralmutagenesis" title="sec"> <div class="title" tagx="title" title="title">
Depletion of intracellular nucleotide pools and enhancement of viral mutagenesis</div> <p id="Par8">Viral replication places an increased cellular burden on the availableÂ nucleotide pools, which can be targeted to compromise viral replication. Inosine-5â€²-monophosphate dehydrogenase (IMPDH) catalyzes an essential step in the biosynthesis of guanine nucleotides, i.e., conversion of IMP to xanthosine monophosphate (XMP). XMP leads to the de novo formation of guanosine monophosphate (GMP), a crucial molecule for numerous cellular processes. Inhibition of IMPDH leads to depletion of intracellular guanine nucleotide (GTP /dGTP) levels and thus limits RNA and DNA synthesis needed for viral replication. Examples of IMPDH inhibitors are VX-497, a noncompetitive IMPDH-inhibitor with broad-spectrum activity [<a href="#CR18">18</a>], as well as ribavirin, which is a competitive IMPDH inhibitor.</p> <p id="Par9">In addition to dGTP-depletion, ribavirin also enhances viral mutagenesis byÂ the incorrect substitution of ribaivirin triphosphate (RTP) in place ofÂ GTP into the viral RNA as most viral polymerases lack proofreading capacity [<a href="#CR19">19</a>]. However, despite a well-documented history of broad-spectrum antiviral activity, ribavirin displayed strikingly weak antiviral activity against SARS-CoV, MERS-CoV, andÂ SARS-CoV-2 [<a href="#CR20">20</a>]. Coronaviruses possess a unique bifunctional enzyme called nsp14, which methylates the viral RNA cap and excises erroneous mutagenic nucleotides that are inserted by the error-prone nsp12 polymerase. This unique ability allows the coronavirus nsp14 to excise RTP from the viral genome limiting the antiviral activity of ribavirin. This extraordinary RNA correction machinery imparts nucleoside drug resistance to coronaviruses and is theÂ likely source of their RNA-based genome expansion [<a href="#CR21">21</a>].</p> </div> <div class="targetingpro-viralkinasesandvesicular/secretorypathways" title="sec"> <div class="title" tagx="title" title="title">
Targeting pro-viral kinases and vesicular/secretory pathways</div> <p id="Par10">Recent genome-wide approaches using small interfering RNA (siRNA) or CRISPR assays targeting the cellular â€œkinomeâ€� have highlighted pro-viral cellular factors, which can serve as novel targets forÂ the design of HDAs. As anÂ example, de Wilde et al. performed a siRNA screen targeting the human kinome to identify host kinases relevant for SARS-CoV infection [<a href="#CR22">22</a>]. Their work alsoÂ showed other proteins that promote SARS-CoV replication such as the coatomer protein complex (COPB2) and Golgi-specific brefeldin A resistant guanine nucleotide factor 1 (GBF1). Such examples underscore the importance of the vesicular and secretory pathways for viral replication. Similarly, Lesche et al. uncovered 133 genes required for the spread of multiple influenza virus strains. Further studies involving these target genes and 43 approved drugs showed that urea-based kinase inhibitors possess high antiviral activity and low cytotoxicity offering aÂ superior therapeutic window. These inhibitors also showed substantial activity against other viruses such as cowpox virus (CPXV) and herpes simplex virus (HSV1) [<a href="#CR23">23</a>].</p> </div> <div class="sigmareceptorsandvirus-inducederstress" title="sec"> <div class="title" tagx="title" title="title">
Sigma receptors and virus-induced ER stress</div> <p id="Par11">Gordon et al. expressed 26 tagged, SARS-CoV-2 proteins in human cells to identify proteins that physically associated with each viral protein. They identified overÂ 300 host proteins that bind to SARS-CoV-2 proteins, many of which are suspected of contributing to theÂ viral life cycle. Among the interactors were Sigma1 and Sigma2 proteins. The authors tested 69 approved or clinical-stage compounds and found that theÂ drug compounds targeting either theÂ mRNA translation and/or regulators of Sigma1 and Sigma2 receptors displayed a prominentÂ antiviral effect. Sigma1 receptors are localized at the endoplasmic reticulum (ER)Â membranes and the mitochondria-associated membranes (MAM). They are multifunctional proteins involved in essential cellular processes, including protein folding, degradation, ER traffickingÂ and oxidative stress, cell survival, and mitochondrial function [<a href="#CR24">24</a>]. Sigma1 receptors have previously been implicated in the regulation of Hepatitis C [<a href="#CR25">25</a>] and Sendai virus replication via modulation of ER stress and the antiviral innate immune response [<a href="#CR26">26</a>]. Since multiple viruses induce ER stress, the Sigma1 receptor could be possible therapeutic target.</p> <p id="Par12">In addition to the above, modulation of epigenetic changes to the host genome [<a href="#CR27">27</a>], potentiation of immune responses and regulation of cytokine storms are also feasible strategies for theÂ development of broad-spectrum, therapeuticÂ agents. The latter twoÂ strategies have been extensively reviewed for COVID-19 management and are not discussed here.</p> </div> </div> <div class="currentstatusandrisk-benefitanalysisofhdasanddaas" title="sec"> <div class="title" tagx="title" title="title">
Current status and risk-benefit analysis of HDAs and DAAs</div> <p id="Par13">Of the 92 approved antiviral drugs, HIV and HCV drugs account for two-thirds of all approvals [<a href="#CR28">28</a>]. The antiviral landscape is dominated by small molecules which constituteÂ 87% of approved antiviral agents. Despite extensive studies involving host-targets and their relevance in the antiviral life cycle, the number of approved antivirals directed against host proteins has lagged significantly. Only about 10% of all approved antivirals are directed against host-proteins, half of which are interferon-related biologics [<a href="#CR28">28</a>, <a href="#CR29">29</a>] (Fig.Â <a href="#Fig1">1</a>). </p><div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Fig.Â 1</span></a></div>   <p>(Top) pie chart depicting the ratio of approved antiviral agents that are virus-directed vs. those that are host-directed. For clarification, interferons are represented as a separate class. (Bottom) list of approved HDAs and their mechanisms of action</p>   </div> <p /> <p id="Par14">TheÂ clinical development of and application ofÂ an antiviral agent requires careful consideration of its putative benefit <i>vis a vis</i> its potential side-effects (TableÂ <a href="#Tab1">1</a>). When targeting host proteins, the topic of drug-related adverse events (DAEs) and toxicity is inescapable. DAEs can be assigned to one of two sources i.e. chemical-related toxicities or pathway-related toxicities. The chemical toxicity of a potential drug is driven primarily by undesirable chemical liabilities of reactive, labile functional groups. On the other hand, pathway-related toxicity is a function of the biological pathway that is targeted for therapeuticÂ intervention. While chemistry associated toxicities routinely encumber any drug development program, pathway-related toxicities are more complex. A common benefit of DAAs is that they are designed to hit a viral protein and not a host protein, thereby reducing theoretical concerns of off-target effects. However, even with DAAs, off-target effects are unavoidable as there are overÂ tens of thousands of knownÂ host proteins. <div class="table-wrap_UNKNOWN" id="Tab1"><span class="label" tagx="label" title="label">TableÂ 1</span> </div></p><p>Potential advantages and disadvantages of HDAs (host targeted antivirals)</p>  <table frame="hsides" rules="groups"> <thead> <tr> <th align="left">Benefits</th> <th align="left">Risks</th> </tr> </thead> <tbody> <tr> <td align="left">Broad-spectrum activity against different virus types that use the same host target</td> <td align="left">Potential of host pathway-related toxicity</td> </tr> <tr> <td align="left">Pan-genotype/serotype coverage</td> <td align="left">Host/population-specific polymorphisms on differential host target expression</td> </tr> <tr> <td align="left">High barrier to theÂ development of genetic resistance</td> <td align="left">Poor translation of in vitro to in vivo (animal models)</td> </tr> <tr> <td align="left">Numerous putative drug targets for cross-class combination therapy</td> <td align="left">Complex mechanism of actionâ€"Deconvolution of target and target-specific effects challenging</td> </tr> <tr> <td align="left">Can be available before epidemics and pandemics for emerging/new viruses</td> <td align="left">Possibility of redundant host mechanisms that ease virus dependence on select target</td> </tr> <tr> <td align="left">Potential for preemptive development of agents before a realized viral threat</td> <td align="left">May require direct-acting antivirals as a combination therapy for maximum benefit</td> </tr> </tbody> </table>  <p /> <p id="Par15">For HDAs, such considerations must take center stage as targeting proteins or pathways that are important to cellularÂ development and homeostasis should be avoided. The cardiac toxicity of HCQÂ in the COVID-19 settingÂ effectively illustrates this point [<a href="#CR8">8</a>â€"<a href="#CR10">10</a>]. In the development of HDAs, the prospect of pathway-related toxicities will require more rigorous investigation inÂ the preclinical and translational stages of drug development. These concerns must be tempered by the fact that such liabilities are routinely faced in the development of drugs for non-viralÂ diseasesÂ where host proteins are consistently pursued, including diabetes, oncology and autoimmune diseases. Thus, modern drug development teams are adequately prepared toÂ include such considerations during the mechanism of action and translational workup on a drug candidate.</p> <p id="Par16">Respiratory viral infections such as those caused byÂ influenza and coronaviruses, orÂ hemorrhagic fevers that areÂ triggered byÂ dengue or zika viruses with pandemic potential are acute infections that can resolve within a few weeks. Therefore, treatment strategies are characterized by short term use, permitting a higher threshold to accept non-fatal, adverse effects. It is noteworthy, that such risk-benefit analysis was recentlyÂ employed by the FDA and theÂ Data Safety Monitoring Committee in the ATCC-1 trial endorsing an emergency approval of remdesivir for COVID-19. While serious adverse effects (SAEs)Â were reported in 114 of the 541 (21%) patients in the remdesivir group, the approval suggests a higher tolerance for accepting SAEs in favor of the benefits associated with short term use.</p> </div> <div class="conclusion" title="sec"> <div class="title" tagx="title" title="title">
Conclusion</div> <p id="Par17">The SARS-CoV-2 pandemic underscores the need for both DAAs and HDAs in our antiviral armamentarium. Broad-spectrum antiviral agents such as HDAs can be readily deployed on a large scale to blunt viral spread while effective vaccines or DAAs are beingÂ developed. Although SARS-CoV-2 mayÂ fall short of triggering an apocalyptic scenario, it is an omen to looming viruses of known and unknown origins. Our antiviral drug development philosophy requires a careful reconsideration to include host-specific therapeutic targets for the management of viral infections.</p> </div> </div> <div class="back" title="back"> <div class="fn-group" title="fn-group"> <div class="fn-type-" title=""> <p><b>Publisher's Note</b></p> <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p> </div> </div> <div class="ack" title="ack"> <div class="title" tagx="title" title="title">
Acknowledgements</div> <p>Not applicable.</p> </div> <div class="title" tagx="title" title="title">
Authorsâ€™ contributions</div> <p>VC and AM contributed equally to the writing. Both authors read and approved the final manuscript.</p> <div class="title" tagx="title" title="title">
Funding</div> <p>Not applicable. The authors declare that no funding was required for this article.</p> <div class="title" tagx="title" title="title">
Availability of data</div> <p>Not applicable.</p> <div class="title" tagx="title" title="title">
Ethics approval and consent to participate</div> <p id="Par18">Not applicable.</p> <div class="title" tagx="title" title="title">
Consent for publication</div> <p id="Par19">Not applicable.</p> <div class="title" tagx="title" title="title">
Competing interests</div> <p id="Par20">The authors declare that they have no commercial or competing interests.</p> <div class="references">
References</div> <div tag="ref-list"> <ul> <div class="title" tagx="title" title="title">
References</div> <li tag="ref"><a name="CR1" /><span class="label" tagx="label" title="label">1.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wu</span><span class="given-names" tagx="given-names" title="given-names">F</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">A new coronavirus associated with human respiratory disease in China</span><span class="source" tagx="source" title="source">Nature</span><span class="year" tagx="year" title="year">2020</span><span class="volume" tagx="volume" title="volume">579</span><span class="fpage" tagx="fpage" title="fpage">265</span><span class="lpage" tagx="lpage" title="lpage">269</span><span class="pub-id"><a href="https://dx.doi.org/10.1038/s41586-020-2008-3">10.1038/s41586-020-2008-3</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32015508">32015508</a></span></span></li> <li tag="ref"><a name="CR2" /><span class="label" tagx="label" title="label">2.</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Novel Coronavirus (2019-nCoV) situation reports.</span></li> <li tag="ref"><a name="CR3" /><span class="label" tagx="label" title="label">3.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">DiMasi</span><span class="given-names" tagx="given-names" title="given-names">JA</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Grabowski</span><span class="given-names" tagx="given-names" title="given-names">HG</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hansen</span><span class="given-names" tagx="given-names" title="given-names">RW</span></span></span><span class="mixed-article-title" title="mixed-article-title">Innovation in the pharmaceutical industry: new estimates of R&amp;amp;D costs</span><span class="source" tagx="source" title="source">J Health Econ</span><span class="year" tagx="year" title="year">2016</span><span class="volume" tagx="volume" title="volume">47</span><span class="fpage" tagx="fpage" title="fpage">20</span><span class="lpage" tagx="lpage" title="lpage">33</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.jhealeco.2016.01.012">10.1016/j.jhealeco.2016.01.012</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26928437">26928437</a></span></span></li> <li tag="ref"><a name="CR4" /><span class="label" tagx="label" title="label">4.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Liu</span><span class="given-names" tagx="given-names" title="given-names">J</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro</span><span class="source" tagx="source" title="source">Cell Discov</span><span class="year" tagx="year" title="year">2020</span><span class="volume" tagx="volume" title="volume">6</span><span class="fpage" tagx="fpage" title="fpage">16</span><span class="pub-id"><a href="https://dx.doi.org/10.1038/s41421-020-0156-0">10.1038/s41421-020-0156-0</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32194981">32194981</a></span></span></li> <li tag="ref"><a name="CR5" /><span class="label" tagx="label" title="label">5.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gao</span><span class="given-names" tagx="given-names" title="given-names">J</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yang</span><span class="given-names" tagx="given-names" title="given-names">X</span></span></span><span class="mixed-article-title" title="mixed-article-title">Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies</span><span class="source" tagx="source" title="source">Biosci Trends</span><span class="year" tagx="year" title="year">2020</span><span class="volume" tagx="volume" title="volume">14</span><span class="fpage" tagx="fpage" title="fpage">72</span><span class="lpage" tagx="lpage" title="lpage">73</span><span class="pub-id"><a href="https://dx.doi.org/10.5582/bst.2020.01047">10.5582/bst.2020.01047</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32074550">32074550</a></span></span></li> <li tag="ref"><a name="CR6" /><span class="label" tagx="label" title="label">6.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Geleris</span><span class="given-names" tagx="given-names" title="given-names">J</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Observational study of hydroxychloroquine in hospitalized patients with Covid-19</span><span class="source" tagx="source" title="source">N Engl J Med</span><span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.1056/NEJMoa2012410">10.1056/NEJMoa2012410</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32379955">32379955</a></span></span></li> <li tag="ref"><a name="CR7" /><span class="label" tagx="label" title="label">7.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rosenberg</span><span class="given-names" tagx="given-names" title="given-names">ES</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State</span><span class="source" tagx="source" title="source">JAMA</span><span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.1001/jama.2020.8630">10.1001/jama.2020.8630</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32840598">32840598</a></span></span></li> <li tag="ref"><a name="CR8" /><span class="label" tagx="label" title="label">8.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mercuro</span><span class="given-names" tagx="given-names" title="given-names">NJ</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19)</span><span class="source" tagx="source" title="source">JAMA Cardiol</span><span class="year" tagx="year" title="year">2019</span><span class="pub-id"><a href="https://dx.doi.org/10.1001/jamacardio.2020.1834">10.1001/jamacardio.2020.1834</a></span></span></li> <li tag="ref"><a name="CR9" /><span class="label" tagx="label" title="label">9.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Saleh</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">The effect of chloroquine, hydroxychloroquine and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection</span><span class="source" tagx="source" title="source">Circ Arrhythm Electrophysiol</span><span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.1161/CIRCEP.120.008662">10.1161/CIRCEP.120.008662</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/33003964">33003964</a></span></span></li> <li tag="ref"><a name="CR10" /><span class="label" tagx="label" title="label">10.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chorin</span><span class="given-names" tagx="given-names" title="given-names">E</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">QT Interval Prolongation and Torsade De Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin</span><span class="source" tagx="source" title="source">Heart Rhythm</span><span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.hrthm.2020.05.014">10.1016/j.hrthm.2020.05.014</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32407884">32407884</a></span></span></li> <li tag="ref"><a name="CR11" /><span class="label" tagx="label" title="label">11.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Beigel</span><span class="given-names" tagx="given-names" title="given-names">JH</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Remdesivir for the Treatment of Covid-19â€"preliminary report</span><span class="source" tagx="source" title="source">N Engl J Med</span><span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.1056/NEJMoa2007764">10.1056/NEJMoa2007764</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32991794">32991794</a></span></span></li> <li tag="ref"><a name="CR12" /><span class="label" tagx="label" title="label">12.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hoffmann</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</span><span class="source" tagx="source" title="source">Cell</span><span class="year" tagx="year" title="year">2020</span><span class="volume" tagx="volume" title="volume">181</span><span class="fpage" tagx="fpage" title="fpage">271</span><span class="lpage" tagx="lpage" title="lpage">280</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.cell.2020.02.052">10.1016/j.cell.2020.02.052</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32142651">32142651</a></span></span></li> <li tag="ref"><a name="CR13" /><span class="label" tagx="label" title="label">13.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kim</span><span class="given-names" tagx="given-names" title="given-names">TS</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Heinlein</span><span class="given-names" tagx="given-names" title="given-names">C</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hackman</span><span class="given-names" tagx="given-names" title="given-names">RC</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nelson</span><span class="given-names" tagx="given-names" title="given-names">PS</span></span></span><span class="mixed-article-title" title="mixed-article-title">Phenotypic analysis of mice lacking the Tmprss2-encoded protease</span><span class="source" tagx="source" title="source">Mol Cell Biol</span><span class="year" tagx="year" title="year">2006</span><span class="volume" tagx="volume" title="volume">26</span><span class="fpage" tagx="fpage" title="fpage">965</span><span class="lpage" tagx="lpage" title="lpage">975</span><span class="pub-id"><a href="https://dx.doi.org/10.1128/MCB.26.3.965-975.2006">10.1128/MCB.26.3.965-975.2006</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16428450">16428450</a></span></span></li> <li tag="ref"><a name="CR14" /><span class="label" tagx="label" title="label">14.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Laporte</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Naesens</span><span class="given-names" tagx="given-names" title="given-names">L</span></span></span><span class="mixed-article-title" title="mixed-article-title">Airway proteases: an emerging drug target for influenza and other respiratory virus infections</span><span class="source" tagx="source" title="source">Curr Opin Virol</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">24</span><span class="fpage" tagx="fpage" title="fpage">16</span><span class="lpage" tagx="lpage" title="lpage">24</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.coviro.2017.03.018">10.1016/j.coviro.2017.03.018</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28414992">28414992</a></span></span></li> <li tag="ref"><a name="CR15" /><span class="label" tagx="label" title="label">15.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Iwata-Yoshikawa</span><span class="given-names" tagx="given-names" title="given-names">N</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection</span><span class="source" tagx="source" title="source">J Virol</span><span class="year" tagx="year" title="year">2019</span><span class="pub-id"><a href="https://dx.doi.org/10.1128/jvi.01815-18">10.1128/jvi.01815-18</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30626688">30626688</a></span></span></li> <li tag="ref"><a name="CR16" /><span class="label" tagx="label" title="label">16.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhou</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Protease inhibitors targeting coronavirus and filovirus entry</span><span class="source" tagx="source" title="source">Antiviral Res</span><span class="year" tagx="year" title="year">2015</span><span class="volume" tagx="volume" title="volume">116</span><span class="fpage" tagx="fpage" title="fpage">76</span><span class="lpage" tagx="lpage" title="lpage">84</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.antiviral.2015.01.011">10.1016/j.antiviral.2015.01.011</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25666761">25666761</a></span></span></li> <li tag="ref"><a name="CR17" /><span class="label" tagx="label" title="label">17.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Braun</span><span class="given-names" tagx="given-names" title="given-names">E</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sauter</span><span class="given-names" tagx="given-names" title="given-names">D</span></span></span><span class="mixed-article-title" title="mixed-article-title">Furin-mediated protein processing in infectious diseases and cancer</span><span class="source" tagx="source" title="source">Clin Transl Immunology</span><span class="year" tagx="year" title="year">2019</span><span class="volume" tagx="volume" title="volume">8</span><span class="fpage" tagx="fpage" title="fpage">e1073</span><span class="pub-id"><a href="https://dx.doi.org/10.1002/cti2.1073">10.1002/cti2.1073</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31406574">31406574</a></span></span></li> <li tag="ref"><a name="CR18" /><span class="label" tagx="label" title="label">18.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Markland</span><span class="given-names" tagx="given-names" title="given-names">W</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">McQuaid</span><span class="given-names" tagx="given-names" title="given-names">TJ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jain</span><span class="given-names" tagx="given-names" title="given-names">J</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kwong</span><span class="given-names" tagx="given-names" title="given-names">AD</span></span></span><span class="mixed-article-title" title="mixed-article-title">Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon</span><span class="source" tagx="source" title="source">Antimicrob Agents Chemother</span><span class="year" tagx="year" title="year">2000</span><span class="volume" tagx="volume" title="volume">44</span><span class="fpage" tagx="fpage" title="fpage">859</span><span class="lpage" tagx="lpage" title="lpage">866</span><span class="pub-id"><a href="https://dx.doi.org/10.1128/aac.44.4.859-866.2000">10.1128/aac.44.4.859-866.2000</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10722482">10722482</a></span></span></li> <li tag="ref"><a name="CR19" /><span class="label" tagx="label" title="label">19.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Crotty</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen</span><span class="source" tagx="source" title="source">Nat Med</span><span class="year" tagx="year" title="year">2000</span><span class="volume" tagx="volume" title="volume">6</span><span class="fpage" tagx="fpage" title="fpage">1375</span><span class="lpage" tagx="lpage" title="lpage">1379</span><span class="pub-id"><a href="https://dx.doi.org/10.1038/82191">10.1038/82191</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11100123">11100123</a></span></span></li> <li tag="ref"><a name="CR20" /><span class="label" tagx="label" title="label">20.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Choy</span><span class="given-names" tagx="given-names" title="given-names">KT</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro</span><span class="source" tagx="source" title="source">Antiviral Res</span><span class="year" tagx="year" title="year">2020</span><span class="volume" tagx="volume" title="volume">178</span><span class="fpage" tagx="fpage" title="fpage">104786</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.antiviral.2020.104786">10.1016/j.antiviral.2020.104786</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32251767">32251767</a></span></span></li> <li tag="ref"><a name="CR21" /><span class="label" tagx="label" title="label">21.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ferron</span><span class="given-names" tagx="given-names" title="given-names">F</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA</span><span class="source" tagx="source" title="source">Proc Natl Acad Sci U S A</span><span class="year" tagx="year" title="year">2018</span><span class="volume" tagx="volume" title="volume">115</span><span class="fpage" tagx="fpage" title="fpage">E162</span><span class="lpage" tagx="lpage" title="lpage">E171</span><span class="pub-id"><a href="https://dx.doi.org/10.1073/pnas.1718806115">10.1073/pnas.1718806115</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29279395">29279395</a></span></span></li> <li tag="ref"><a name="CR22" /><span class="label" tagx="label" title="label">22.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">de Wilde</span><span class="given-names" tagx="given-names" title="given-names">AH</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wannee</span><span class="given-names" tagx="given-names" title="given-names">Kazimier F</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Scholte</span><span class="given-names" tagx="given-names" title="given-names">FEM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Goeman</span><span class="given-names" tagx="given-names" title="given-names">JJ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">ten Dijke</span><span class="given-names" tagx="given-names" title="given-names">P</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Snijder</span><span class="given-names" tagx="given-names" title="given-names">EJ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kikkert</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">van Martijn</span><span class="given-names" tagx="given-names" title="given-names">J</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hemert</span><span class="given-names" tagx="given-names" title="given-names">SP</span></span></span><span class="mixed-article-title" title="mixed-article-title">A kinome-wide small interfering rna screen identifies proviral and antiviral host factors in severe acute respiratory syndrome coronavirus replication, including double-stranded rna-activated protein kinase and early secretory pathway proteins</span><span class="source" tagx="source" title="source">J Virol.</span><span class="year" tagx="year" title="year">2015</span><span class="volume" tagx="volume" title="volume">89</span><span class="issue" tagx="issue" title="issue">16</span><span class="fpage" tagx="fpage" title="fpage">8318</span><span class="lpage" tagx="lpage" title="lpage">8333</span><span class="pub-id"><a href="https://dx.doi.org/10.1128/JVI.01029-15">10.1128/JVI.01029-15</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26041291">26041291</a></span></span></li> <li tag="ref"><a name="CR23" /><span class="label" tagx="label" title="label">23.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lesch</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">RNAi-based small molecule repositioning reveals clinically approved urea-based kinase inhibitors as broadly active antivirals</span><span class="source" tagx="source" title="source">PLoS Pathog</span><span class="year" tagx="year" title="year">2019</span><span class="volume" tagx="volume" title="volume">15</span><span class="fpage" tagx="fpage" title="fpage">e1007601</span><span class="pub-id"><a href="https://dx.doi.org/10.1371/journal.ppat.1007601">10.1371/journal.ppat.1007601</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30883607">30883607</a></span></span></li> <li tag="ref"><a name="CR24" /><span class="label" tagx="label" title="label">24.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hayashi</span><span class="given-names" tagx="given-names" title="given-names">T</span></span></span><span class="mixed-article-title" title="mixed-article-title">Sigma-1 receptor: the novel intracellular target of neuropsychotherapeutic drugs</span><span class="source" tagx="source" title="source">J Pharmacol Sci</span><span class="year" tagx="year" title="year">2015</span><span class="volume" tagx="volume" title="volume">127</span><span class="fpage" tagx="fpage" title="fpage">2</span><span class="lpage" tagx="lpage" title="lpage">5</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.jphs.2014.07.001">10.1016/j.jphs.2014.07.001</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25704011">25704011</a></span></span></li> <li tag="ref"><a name="CR25" /><span class="label" tagx="label" title="label">25.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Friesland</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mingorance</span><span class="given-names" tagx="given-names" title="given-names">L</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chung</span><span class="given-names" tagx="given-names" title="given-names">J</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chisari</span><span class="given-names" tagx="given-names" title="given-names">FV</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gastaminza</span><span class="given-names" tagx="given-names" title="given-names">P</span></span></span><span class="mixed-article-title" title="mixed-article-title">Sigma-1 receptor regulates early steps of viral RNA replication at the onset of hepatitis C virus infection</span><span class="source" tagx="source" title="source">J Virol</span><span class="year" tagx="year" title="year">2013</span><span class="volume" tagx="volume" title="volume">87</span><span class="fpage" tagx="fpage" title="fpage">6377</span><span class="lpage" tagx="lpage" title="lpage">6390</span><span class="pub-id"><a href="https://dx.doi.org/10.1128/JVI.03557-12">10.1128/JVI.03557-12</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23536676">23536676</a></span></span></li> <li tag="ref"><a name="CR26" /><span class="label" tagx="label" title="label">26.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yang</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Control of antiviral innate immune response by protein geranylgeranylation</span><span class="source" tagx="source" title="source">Sci Adv</span><span class="year" tagx="year" title="year">2019</span><span class="volume" tagx="volume" title="volume">5</span><span class="fpage" tagx="fpage" title="fpage">eaav7999</span><span class="pub-id"><a href="https://dx.doi.org/10.1126/sciadv.aav7999">10.1126/sciadv.aav7999</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31149635">31149635</a></span></span></li> <li tag="ref"><a name="CR27" /><span class="label" tagx="label" title="label">27.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nehme</span><span class="given-names" tagx="given-names" title="given-names">Z</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pasquereau</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Herbein</span><span class="given-names" tagx="given-names" title="given-names">G</span></span></span><span class="mixed-article-title" title="mixed-article-title">Control of viral infections by epigenetic-targeted therapy</span><span class="source" tagx="source" title="source">Clin Epigenetics</span><span class="year" tagx="year" title="year">2019</span><span class="volume" tagx="volume" title="volume">11</span><span class="fpage" tagx="fpage" title="fpage">55</span><span class="pub-id"><a href="https://dx.doi.org/10.1186/s13148-019-0654-9">10.1186/s13148-019-0654-9</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30917875">30917875</a></span></span></li> <li tag="ref"><a name="CR28" /><span class="label" tagx="label" title="label">28.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chaudhuri</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Symons</span><span class="given-names" tagx="given-names" title="given-names">JA</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Deval</span><span class="given-names" tagx="given-names" title="given-names">J</span></span></span><span class="mixed-article-title" title="mixed-article-title">Innovation and trends in the development and approval of antiviral medicines: 1987â€"2017 and beyond</span><span class="source" tagx="source" title="source">Antiviral Res</span><span class="year" tagx="year" title="year">2018</span><span class="volume" tagx="volume" title="volume">155</span><span class="fpage" tagx="fpage" title="fpage">76</span><span class="lpage" tagx="lpage" title="lpage">88</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.antiviral.2018.05.005">10.1016/j.antiviral.2018.05.005</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29758235">29758235</a></span></span></li> <li tag="ref"><a name="CR29" /><span class="label" tagx="label" title="label">29.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">De Clercq</span><span class="given-names" tagx="given-names" title="given-names">E</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Li</span><span class="given-names" tagx="given-names" title="given-names">G</span></span></span><span class="mixed-article-title" title="mixed-article-title">Approved antiviral drugs over the past 50 years</span><span class="source" tagx="source" title="source">Clin Microbiol Rev</span><span class="year" tagx="year" title="year">2016</span><span class="volume" tagx="volume" title="volume">29</span><span class="fpage" tagx="fpage" title="fpage">695</span><span class="lpage" tagx="lpage" title="lpage">747</span><span class="pub-id"><a href="https://dx.doi.org/10.1128/CMR.00102-15">10.1128/CMR.00102-15</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27281742">27281742</a></span></span></li> </ul> </div> </div>  </body></html>